GRAIL Inc. (NASDAQ: GRAL) AI-Powered Stock Analysis
See how GRAIL Inc. scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.
GRAL●NASDAQ
HealthcareBiotechnology
$64.42
$2.35(3.52%)
U.S. Market opens in 15h 54m
GRAIL Inc. (NASDAQ: GRAL) AI-Powered Stock Analysis
See how GRAIL Inc. scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerGRAIL Inc. (NASDAQ: GRAL) Stock Overall Grade
GRAIL Inc.'s grade for its NASDAQ listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to GRAIL Inc.'s overall NASDAQ stock rating.
Forecast
A+Score
100/100Financial Growth
CScore
40/100Fundamental Growth
DScore
30/100Key Ratios
C+Score
55/100Sector Comparison
BScore
65/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
97/100Analyst Consensus
BScore
63/100GRAIL Inc. (NASDAQ: GRAL) AI-Powered Stock Analysis
On the NASDAQ, GRAL demonstrates Good performance with an overall Forecast Score of 100/100 (A+), reflecting high confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (30/100, D) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (65/100, B) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (97/100, A+), the NASDAQ-listed stock shows competitive strength. Analyst Consensus (63/100, B) suggests Moderate divergence in outlook.(NASDAQ: GRAL) Component Analysis Explained
Understand the key factors behind each GRAIL Inc. (NASDAQ: GRAL) stock grade, including financials, comparisons, and forecasts.